Gea has invested in a new multimillion-Euro solid dosage facility. In May this year, the company will officially open its recently expanded Pharma Solids Center (GPSC) in Wommelgem, Belgium.
Wommelgem/Belgium — With a total footprint of 1,100 m2, including 200 m2 of technical space, the investment applies modern technology in solid dosage form testing, development and optimization. The facility offers a full range of batch and continuous process technologies to produce pharmaceutical solid dosage forms.
Some of the key application areas will include continuous wet granulation and drying technologies, continuous direct compression, integrated small-scale granulation and drying, flexible fluid bed processing, high performance tablet coating technology, and the ability to optimize pellet and Mups formulations. The solids centre will offer customer demonstrations and trials, training sessions, hands-on lab experience, product development assistance, CQA evaluation support and updates.
“The expanded facility represents our continual investment in the global pharmaceutical market and, in particular, oral solid dosage (OSD) form technology,” said Dr Marcus Michel, Executive Vice President of GEA’s pharma business. “Whether our customers are working with batch-based or continuous processes, the GPSC now offers an even wider range of innovative solutions than ever before.”
“The needs of drug manufacturers are critical and individual; the newly expanded GPSC has been created to meet those needs. With our unparalleled history of expertise in processing OSDs, from pills to pellets to MUPS, and our tried and tested technologies, I am convinced that we can continue to help our customers to get their products to market faster in a cost-effective way,” Marcus Michel adds.
The opening celebration of the new solids centre will be held during interpack in Düsseldorf.